PDF(1689 KB)
Clinical effect and mechanism of total glucosides of paeony in the adjuvant therapy for children with Henoch-Schönlein purpura nephritis: a prospective randomized controlled study
SHAO Kuan-Furong, GUAN Feng-Jun, DONG Chen
Chinese Journal of Contemporary Pediatrics ›› 2021, Vol. 23 ›› Issue (1) : 49-54.
PDF(1689 KB)
PDF(1689 KB)
Clinical effect and mechanism of total glucosides of paeony in the adjuvant therapy for children with Henoch-Schönlein purpura nephritis: a prospective randomized controlled study
Objective To study the clinical effect and mechanism of total glucosides of paeony (TGP) in the adjuvant therapy for children with Henoch-Schönlein purpura nephritis (HSPN). Methods Sixty-four HSPN children with moderate proteinuria were divided into a TGP treatment group (n=34) and a routine treatment group (n=30) using a random number table. Thirty healthy children who underwent physical examination were enrolled as the healthy control group. The children in the routine treatment group were given conventional treatment alone, and those in the observation group were given TGP in addition to the conventional treatment. The two groups were compared in the clinical outcome after 4 weeks of treatment. The proportion of follicular helper T (Tfh) cells in peripheral blood and the plasma levels of interleukin-21 (IL-21) and interleukin-4 (IL-4) were measured in the healthy control group and the two HSPN groups. The changes in serum cystatin C (CysC) level and urinary alpha 1-microglobulin (A1M) concentration were compared before and after treatment in the two HSPN groups. Results Compared with the healthy children before treatment, the children with HSPN had higher proportion of Tfh cells and expression levels of IL-21 and IL-4 (P < 0.01). The TGP treatment group had a higher overall response rate to treatment than the routine treatment group (94% vs 67%, P < 0.05). After treatment, both groups had reductions in the proportion of Tfh cells in peripheral blood, the expression levels of IL-21, IL-4, serum CysC, and urinary A1M concentration. The TGP treatment group had greater reductions in these indices than the routine treatment group (P < 0.01). Conclusions TGP has a marked clinical effect in the treatment of HSPN and can reduce the inflammatory response of the kidney and exert a protective effect on the kidney by inhibiting the proliferation of Tfh cells and downregulating the expression of IL-21 and IL-4 in plasma.
Henoch-Schönlein purpura nephritis / Total glucosides of paeony / Follicular helper T cell / Cytokine / Child
[1] Pohl M. Henoch-Schönlein purpura nephritis[J]. Pediatr Nephrol, 2015, 30(2):245-252.
[2] 丁艳, 尹薇, 何学莲, 等. 儿童过敏性紫癜急性期免疫功能探讨[J]. 中国免疫学杂志, 2013, 29(5):518-521.
[3] 齐海花, 何磊, 黄占强, 等. 不同分型过敏性紫癜患者外周血Th1/Th2型细胞因子的相关性研究[J]. 河北医学, 2019, 25(6):996-998.
[4] 王强, 史洋溢, 曹玫, 等. Th17细胞/Treg细胞失衡在儿童过敏性紫癜发病机制中的作用[J]. 中国实验血液学杂志, 2015, 23(5):1391-1396.
[5] Locci M, Wu JE, Arumemi F, et al. Activin a programs the differentiation of human TFH cells[J]. Nat Immunol, 2016, 17(8):976-984.
[6] 赵洁茹, 郝春秋, 贾战生. 与滤泡辅助性T(Tfh)细胞分化发育相关的主要转录因子[J]. 细胞与分子免疫学杂志, 2017, 33(2):261-265.
[7] Yusuf I, Kageyama R, Monticelli L, et al. Germinal center T follicular helper cell IL-4 production is dependent on signaling lymphocytic activation molecule receptor (CD150)[J]. J Immunol, 2010, 185(1):190-202.
[8] Blanco P, Ueno H, Schmitt N. T follicular helper (Tfh) cells in lupus:activation and involvement in SLE pathogenesis[J]. Eur J Immunol, 2016, 46(2):281-290.
[9] 王春美, 罗源, 王颖超, 等. 滤泡辅助性T细胞和滤泡调节性T细胞在儿童过敏性紫癜发病中的作用[J]. 中国当代儿科杂志, 2015, 17(10):1084-1087.
[10] 张真如. 尿蛋白四项与IGF-1、MCP-1水平在过敏性紫癜患儿中的变化及与肾损伤的关系研究[J]. 国际检验医学杂志, 2018, 39(16):2008-2010.
[11] 祝高红. Cys C及β2-微球蛋白联合检测对过敏性紫癜患儿早期肾损害的诊断价值[J]. 中国急救医学, 2016, 36(z2):75-77.
[12] Zhang L, Wei W. Anti-inflammatory and immunoregulatory effects of paeoniflorin and total glucosides of paeony[J]. Pharmacol Ther, 2020, 207:107452.
[13] 吴佳莹, 羊红玉, 楼燕, 等. 白芍总苷辅助治疗过敏性紫癜的Meta分析[J]. 中华临床医师杂志(电子版), 2015, 9(19):3597-3603.
[14] 中华医学会儿科学分会肾脏学组. 紫癜性肾炎诊治循证指南(2016)[J]. 中华儿科杂志, 2017, 55(9):647-651.
[15] 徐铁华. 丹芍汤佐治小儿过敏性紫癜肾炎疗效观察[J]. 儿科药学杂志, 2016, 22(10):21-23.
[16] Nakayamada S, Tanaka Y. T follicular helper (Tfh) cells in autoimmune diseases[J]. Nihon Rinsho Meneki Gakkai Kaishi, 2016, 39(1):1-7.
[17] Spolski R, Leonard WJ. Interleukin-21:a double-edged sword with therapeutic potential[J]. Nat Rev Drug Discov, 2014, 13(5):379-395.
[18] 陈升, 李杨磊, 王元元. 滤泡辅助性T细胞的研究进展[J]. 蚌埠医学院学报, 2019, 44(1):138-140.
[19] Song W, Craft J. T follicular helper cell heterogeneity:time, space, and function[J]. Immunol Rev, 2019, 288(1):85-96.
[20] 吕萌, 沈萃萃. 银屑病患者外周血滤泡辅助性T细胞比例、血清IL-21水平变化及其与病情的关系[J]. 山东医药, 2018, 58(8):93-95.
[21] Niu Q, Kraaijeveld R, Li Y, et al. An overview of T follicular cells in transplantation:spotlight on their clinical significance[J]. Expert Rev Clin Immunol, 2019, 15(12):1249-1262.
[22] 焦晓燕, 郭在培, 陈涛, 等. 白芍总苷治疗过敏性紫癜的临床疗效观察[J]. 临床皮肤科杂志, 2013, 42(8):500-502.
[23] 王芳, 张迎辉. 胱抑素C、纤维蛋白原及24 h尿蛋白定量与紫癜性肾炎患儿肾脏病理分级的相关性研究[J]. 中国当代儿科杂志, 2016, 18(3):233-237.
[24] 张志红. 尿特定蛋白五项测定在过敏性紫癜患儿早期肾损伤的临床应用价值[J]. 中国药物与临床, 2019, 19(12):2079-2080.
